News

PMLive10m
Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition
Merck KGaA has announced that it will be acquiring SpringWorks Therapeutics for approximately $3.9bn. The definitive ...
Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Morningstar7h
Germany's Merck to Buy SpringWorks for $3.9 Billion — Update
Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German ...
Fierce Pharma2d
Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout
Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...
Merck KGaA (ETR:MRK) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
It looks like Merck KGaA (ETR:MRK) is about to go ex-dividend in the next 2 days. The ex-dividend date is two business days before a company's record date in most cases, which is the date on which the ...
Merck absorbs $200 million in tariff costs into its earnings and full-year outlook
Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly ...